OR WAIT 15 SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Characterization of virus-like particles enables process reproducibility and product consistency.
Technology advances and collaboration push more therapies closer to commercialization.
Plasma-based proteins and cell-based therapies have potential to address unmet medical needs.
March 01, 2021
Accelerated drug development timelines must accommodate all crucial elements of nonclinical safety studies.
February 23, 2021
Through the acquisition, Catalent will establish pDNA development and manufacturing services at its Rockville, MD, facility and will gain Delphi’s team of R&D and genetic engineering scientists, technicians, and regulatory specialists.
February 22, 2021
With the acquisition, Eurofins gets Beacon’s G-protein coupled receptor research knowledge and its compound library.
The companies will co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications.
February 18, 2021
The company has completed the expansion of its laboratory facilities to accommodate the development of APIs.
The companies have expanded their agreement to include the research and development of new therapies for influenza and other respiratory viruses.
February 17, 2021
The foundation will provide funding support for the discovery and development of a single-administration, in-vivo gene therapy to cure sickle cell disease, a hereditary blood disease.
February 15, 2021
Nanoform and Herantis have signed a biologics proof of concept agreement for formulation proof of concept projects aimed at improving nasal drug delivery to the brain.
February 10, 2021
Through the agreement, AbbVie will use Caribou’s next-generation Cas12a CRISPR hybrid RNA–DNA genome editing and cell therapy technologies to develop two new CAR-T cell therapies.
February 03, 2021
A task force details its findings of the risks associated with using convalescent plasma using failure mode and effects analysis